Faeth Therapeutics is navigating a striking divergence: eleven analysts have initiated with Buy ratings and targets as high as $70, yet short interest has nearly doubled in a month and now exceeds the entire free float.
The short-side story is the week's defining tension. Short interest jumped 37% in a single session on September 17, reaching 124% of free float — a level that, by definition, means shorts have borrowed and sold more shares than actually trade freely. Over the past month, short interest climbed nearly 50%, a rapid build for any stock, let alone a small-cap biotech with a thin float. Yet the borrow market is telling a calmer story. Availability has tightened sharply this week, falling roughly 69% to 112% — still above 100%, meaning there remains slightly more stock available to borrow than is currently shorted, but the direction is unmistakably tighter. Cost to borrow, at 7.4%, is actually well below the peaks above 25% seen in early August, when the stock was trading closer to $20. The short score has climbed to 72 from around 58 ten days ago, its highest reading of the tracked period. Taken together, the picture is one of rapidly rising bearish conviction running up against a borrow market that has not yet closed the door.
The Street is overwhelmingly bullish, and the initiation wave is still in full swing. Guggenheim opened coverage on September 16 with a Buy and a $70 target — the highest on record. TD Cowen initiated Buy on September 9. Needham and Raymond James both launched with positive ratings over the past month, and the consensus target of $57 implies roughly 65% upside to the current price of $34.50. The bull case centres on Piktor, Faeth's oncology candidate advancing through Phase 2 in breast and endometrial cancer, with bulls pointing to the institutional backing and pipeline potential. Bears counter with the standard clinical-stage risks: a single-arm Phase 2 design, tolerability questions on dosing, crowded competitive field in oncology, and an estimated equity value that bulls acknowledge is high relative to current cash generation. The analyst recommendation score ranks in the 99th percentile of the ORTEX universe — essentially as bullish as consensus gets — but EPS momentum ranks in the 6th percentile over 90 days, a reminder the financials remain deeply pre-revenue.
Institutional ownership adds another layer to the picture. Several prominent healthcare-focused funds — Baker Bros., Avoro Capital, RA Capital, Fairmount Funds, and Cormorant Asset Management — all established positions as of the June quarter, many of them fresh builds. Khosla Ventures holds roughly 10% of shares. On the insider side, CFO Brian Stephenson made a cluster of open-market purchases in late June and early July across roughly $490,000 in total notional value, buying at prices between $23 and $27. Those trades were not under a 10b5-1 plan, making them discretionary buys at roughly a 30% discount to the current price. The activist register carries no 13D filers — all Schedule 13G filings, indicating passive stakes — though ICS Opportunities and Caligan Partners both materially reduced their positions in amended filings since May, and StemPoint Capital has exited entirely. As always with 13D/G disclosures, stakes are as-last-disclosed around the 5% threshold, and holders dropping below that level may not file again.
Earnings history adds a further nuance. The last four prints produced a consistent pattern: a mid-single-digit to low-double-digit loss on the day, followed by a strong five-day recovery. The August 11 result was an exception — the stock gained nearly 3% on the day and extended to +15% over five sessions. The next event is scheduled for November 12, which gives the current short positioning roughly eight weeks to play out.
The stock fell 1.8% Friday to close at $34.50, down nearly 8% on the week, while peers were mixed: TYRA gained 17% over the same period and ACRV fell 7.5%. The key variable to watch is whether availability continues to tighten toward the 52-week low of 0.5% — if borrowable supply evaporates while shorts remain this large relative to float, the mechanical setup for a short squeeze becomes significantly more charged heading into the November earnings event.
See the live data behind this article on ORTEX.
Open FTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
